| Prev Close | 0.12 |
| Open | 0.12 |
| Day Low/High | 0.12 / 0.12 |
| 52 Wk Low/High | 0.20 / 0.64 |
| Volume | 856.44K |
| Avg Volume | 2.83M |
| Exchange | AMEX |
| Shares Outstanding | 127.95M |
| Market Cap | 15.35M |
| EPS | -0.10 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
ImmunoCellular Therapeutics Reports Progress In Two Lead Cancer Immunotherapy Programs
Over 100 Patients Screened in Phase 3 ICT-107 Trial in Newly Diagnosed Glioblastoma;
Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'
A defrocked analyst brushes off the serious problems weighing on Northwest Bio. Instead, he jacks the tired 'blame the shorts' excuse to another level.
ImmunoCellular Therapeutics Presents Updated ICT-107 Phase 2 Survival And Immune Response Data At The Society For Neuro-Oncology Annual Meeting 2015
Data support phase 3 registration trial incorporating key design modifications to potentially optimize outcomes
ImmunoCellular Therapeutics Awarded $19.9 Million Grant From California Institute For Regenerative Medicine (CIRM) To Fund ICT-107 Phase 3 Registration Program In Glioblastoma
ICT-107 Phase 3 Trial on Track to Begin in Fourth Quarter
ImmunoCellular Therapeutics Appoints Mark A. Schlossberg And Gregg A. Lapointe To Its Board Of Directors
Mr. Schlossberg and Mr. Lapointe Will Serve as Independent Members of the Board of Directors
